San-Lan Wu

Dr. San-Lan Wu


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
CMChao Mei
Chao Mei
WGWeijing Gong
Weijing Gong
XWXu Wang
Xu Wang
YLYongning Lv
Yongning Lv
YZYu Zhang
Yu Zhang
CZChunqi Zhu
Chunqi Zhu
Ovarian cancer (OC) remains the most fatal disease of gynecologic malignant tumors. Angiogenesis refers to the development of new vessels from pre-existing ones, which is responsible for supplying nutrients and removing metabolic waste. Although not yet completely understood, tumor vascularization is orchestrated by multiple secreted factors and signaling pathways. The most central proangiogenic signal, vascular endothelial growth factor (VEGF)/VEGFR signaling, is also the primary target of initial clinical anti-angiogenic effort. However, the efficiency of therapy has so far been modest due to the low response rate and rapidly emerging acquiring resistance. This review focused on the current understanding of the in-depth mechanisms of tumor angiogenesis, together with the newest reports of clinical trial outcomes and resistance mechanism of anti-angiogenic agents in OC. We also emphatically summarized and analyzed previously reported biomarkers and predictive models to describe the prospect of precision therapy of anti-angiogenic drugs in OC.

28 January 2019 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
WGWei-Jing Gong
Wei-Jing Gong
LMLi-Yun Ma
Li-Yun Ma
LHLei Hu
Lei Hu
YLYong-Ning Lv
Yong-Ning Lv
HHHong Huang
Hong Huang
SWSan-Lan Wu
San-Lan Wu

30 April 2021 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
WGWei-Jing Gong
Wei-Jing Gong
TZTao Zhou
Tao Zhou
JXJia-Qiang Xu
Jia-Qiang Xu
YHYi-Fei Huang
Yi-Fei Huang
LXLi-Ping Xiang
Li-Ping Xiang
SWSan-Lan Wu
San-Lan Wu

1 February 2022 in Xenobiotica
Verified
Journal Article
Closed access
FCFen Chen
Fen Chen
LWLiu Wang
Liu Wang
XZXuejia Zhai
Xuejia Zhai
NWNanxi Wang
Nanxi Wang
YQYanjie Qin
Yanjie Qin
YLYongning Lu
Yongning Lu
Breast cancer resistance protein (BCRP/Abcg2 in human, Bcrp/Abcg2 in rat), a member of the ATP-binding cassette (ABC) transporter family, acts as an efflux pump for xenobiotics, with ability to tra...

11 May 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
YWYang Wang
Yang Wang
DSDan Sun
Dan Sun
YMYan Mei
Yan Mei
SWSan-Lan Wu
San-Lan Wu
XLXinlin Li
Xinlin Li
YTYali Tuo
Yali Tuo
The present study aimed to establish population pharmacokinetic models of latamoxef, as well as its R- and S-epimers, and generate findings to guide the individualized administration of latamoxef in pediatric patients. A total of 145 in-hospital children aged 0.08–10.58 years old were included in this study. Three population pharmacokinetic models of latamoxef and its R- and S-epimers were established. The stability and predictive ability of the final models were evaluated by utilizing goodness-of-fit plots, nonparametric bootstrapping, and normalized prediction distribution errors. The final model of total latamoxef was considered as a basis for the dosing regimen. A two-compartment model with first-order elimination best described the pharmacokinetics of total latamoxef. The population typical values of total latamoxef were as follows: central compartment distribution volume (V1) of 4.84 L, peripheral compartment distribution volume (V2) of 16.18 L, clearance (CL) of 1.00 L/h, and inter-compartmental clearance (Q) of 0.97 L/h. Moreover, R-epimer has a higher apparent volume of distribution and lower clearance than S-epimer. Body surface area (BSA) was identified as the most significant covariate to V, CL, and Q. Specific recommendations are given for dosage adjustment in pediatric patients based on BSA. This study highlights that a BSA-normalized dose of latamoxef was required when treating different bacteria to reach the therapeutic target more effectively.

22 February 2018 in Biomedical Chromatography
Verified
Journal Article
Closed access
PDF file
DLDan Li
Dan Li
GZGang Zhao
Gang Zhao
WAWeipeng Ai
Weipeng Ai
GLGao Li
Gao Li
LSLuqin Si
Luqin Si
SWSan-Lan Wu
San-Lan Wu